Long-term follow-up of hyperprolactinemic women treated with bromocriptine.
Seventy-five women with hyperprolactinemia and demonstrable or suspected prolactinomas were treated with bromocriptine only and followed for 5 to 9 years. Biochemical, radiologic, and clinical responses were generally maintained in the long term, once established in the short term. Underlying mass effects on neurologic and pituitary function tended to improve, and no tumor progression was noted. Hypogonadal symptoms normalized in 68 of 75 women. Bromocriptine responses in long-term follow-up do not demonstrate any cumulative problems not seen in short-term therapy.
D000236:Adenoma / Q000188:drug therapy; D000328:Adult; D000368:Aged; D001971:Bromocriptine / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy; D008598:Menstruation / Q000187:drug effects; D008875:Middle Aged; D010903:Pituitary Gland, Anterior / Q000378:metabolism; D010911:Pituitary Neoplasms / Q000188:drug therapy*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000209:etiology; D011388:Prolactin / Q000378:metabolism*; D013997:Time Factors
D001971:Bromocriptine; D011388:Prolactin